EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Passively Targeted Polymeric Nanocarrier Delivering STAT1 siRNA to the Liver Ameliorates Steatohepatitis and Fibrosis in the Thioacetamide Mouse Model

Klea Mehmetaj, Antea Jorgo, WanLing Foo, Zoltán Cseresnyés, Julian Plitzko iD, Tanveer Ahmed Shaik iD, Quratul Ain, Anuradha Ramoji iD, Sophie Huschke, Ling Xiong, Alexander Zipprich, Jürgen Popp iD und 7 weitere

Biomacromolecules · 2026

DOI: 10.1021/acs.biomac.6c00375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, 2026. Verfasst von Klea Mehmetaj und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care Medicine, Am Klinikum 1, Jena University Hospital, 07747, Jena, Germany. Hauptthemen laut MEDLINE: STAT1 Transcription Factor, RNA, Small Interfering, Liver Cirrhosis, Polymers. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Fonds for Regional Development, German Research Council (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a major complication of chronic liver injury, driven in part by Signal Transducer and Activator of Transcription 1 (Stat1). This study evaluated passively liver-targeted polymeric nanocarriers delivering Stat1 siRNA (siSTAT1) to treat steatohepatitis and fibrosis in a thioacetamide (TAA) mouse model. Two polyplex nanocarriers with different core−corona ratios, EN15 and EN76, were tested in TAA-treated mice and activated human and murine hepatocytes. In vitro, both formulations enabled efficient cellular uptake and Stat1 silencing, reducing TAA-induced lipid accumulation. Through an In vivo approach, mice received TAA for 16 weeks followed by four weeks of siSTAT1 treatment. Both formulations reduced collagen deposition, hepatic inflammation, and fibrosis scores. Notably, EN76, which preferentially targets non-parenchymal cells, showed superior antifibrotic efficacy compared with EN15. These findings highlight Stat1 as a key driver of steatohepatitis and fibrosis and support passive siRNA delivery, particularly via EN76, as a promising therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT1 Transcription FactorRNA, Small InterferingLiver CirrhosisPolymersFatty LiverNanoparticlesAnimalsThioacetamideMiceHumansDisease Models, AnimalMaleLiverHepatocytesMice, Inbred C57BLDrug Carriers

Stichwörter der Autor:innen

STAT1liver fibrosismicellessiRNA deliverysteatohepatitisthioacetamide

Substanzen

ThioacetamideSTAT1 Transcription FactorRNA, Small InterferingPolymersStat1 protein, mouseDrug Carriers

Autor:innen und Institutionen

  • Department of Anesthesiology and Intensive Care Medicine, Am Klinikum 1, Jena University Hospital, 07747, Jena, Germany.
  • Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute (HKI), Applied Systems Biology, Beutenbergstraße 11a07745, Jena, Germany.
  • Leibniz Institute of Photonic Technology (Leibniz-IPHT) Member of the Leibniz Centre for Photonics in Infection Research (LPI), Member of Leibniz Health Technologies, Albert-Einstein-Straße 907745, Jena, Germany.
  • Institute of Physical Chemistry (IPC) and Abbe Center of Photonics (ACP), Friedrich-Schiller-University, Helmholtzweg 407743, Jena, Germany.
  • Clinic for Inner Medicine IV, University Hospital, Am Klinikum 1, Jena07747, Germany.
  • Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University Jena, Neugasse 250774, Jena, Germany.

ORCID-Profile: Julian Plitzko, Tanveer Ahmed Shaik, Anuradha Ramoji, Jürgen Popp, Volker Deckert, Stephanie Schubert, Felix H Schacher, Adrian T Press

Förderung

  • European Fonds for Regional Development
  • German Research Council (DFG)

Zitieren

APA

Mehmetaj, K., Jorgo, A., Foo, W., Cseresnyés, Z., Plitzko, J., Shaik, T. A., Ain, Q., Ramoji, A., Huschke, S., Xiong, L., Zipprich, A., Popp, J., Figge, M. T., Deckert, V., Schubert, S., Gassler, N., Schacher, F. H., Bauer, M., & Press, A. T. (2026). Passively Targeted Polymeric Nanocarrier Delivering STAT1 siRNA to the Liver Ameliorates Steatohepatitis and Fibrosis in the Thioacetamide Mouse Model. Biomacromolecules. https://doi.org/10.1021/acs.biomac.6c00375

Vancouver

Mehmetaj K, Jorgo A, Foo W, Cseresnyés Z, Plitzko J, Shaik TA, et al. Passively Targeted Polymeric Nanocarrier Delivering STAT1 siRNA to the Liver Ameliorates Steatohepatitis and Fibrosis in the Thioacetamide Mouse Model. Biomacromolecules. 2026. doi:10.1021/acs.biomac.6c00375

BibTeX
@article{Mehmetaj2026,
  author = {Mehmetaj, Klea and Jorgo, Antea and Foo, WanLing and Cseresnyés, Zoltán and Plitzko, Julian and Shaik, Tanveer Ahmed and Ain, Quratul and Ramoji, Anuradha and Huschke, Sophie and Xiong, Ling and Zipprich, Alexander and Popp, Jürgen and Figge, Marc Thilo and Deckert, Volker and Schubert, Stephanie and Gassler, Nikolaus and Schacher, Felix H and Bauer, Michael and Press, Adrian T},
  title = {Passively Targeted Polymeric Nanocarrier Delivering STAT1 siRNA to the Liver Ameliorates Steatohepatitis and Fibrosis in the Thioacetamide Mouse Model},
  journal = {Biomacromolecules},
  year = {2026},
  doi = {10.1021/acs.biomac.6c00375}
}
Kostenlos starten →